For most companies, the honest answer is: nobody knows.
Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
On March 31, 2026, the popular HTTP client Axios experienced a supply chain attack, causing two newly published npm packages ...
Anthropic is scrambling to contain the leak, but the AI coding agent is spreading far and wide and being picked apart.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results